| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T170 |
0-306 |
Sentence |
denotes |
Favipiravir Anti-influenza RNA-dependent RNA polymerase inhibitor • In a recent RCT published on a preprint server and comparing 120 COVID-19 patients treated with favipiravir vs. 120 COVID-19 patients receiving umifenovir, higher rates of clinical recovery were observed in patients receiving favipiravir. |
| T171 |
307-482 |
Sentence |
denotes |
The manuscript is publicly available but still to be peer reviewed [30] • Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. |
| T172 |
483-524 |
Sentence |
denotes |
Open-label RCT (NCT04310228, recruiting). |
| T173 |
525-578 |
Sentence |
denotes |
Primary endpoint: clinical cure (follow-up 3 months). |
| T174 |
579-983 |
Sentence |
denotes |
• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. |
| T175 |
984-1033 |
Sentence |
denotes |
Open-label RCT (NCT04303299, not yet recruiting). |
| T176 |
1034-1101 |
Sentence |
denotes |
Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks). |
| T177 |
1102-1210 |
Sentence |
denotes |
• Comparison of hydroxychloroquine plus darunavir/cobicistat vs. standard of care in patients with COVID-19. |
| T178 |
1211-1252 |
Sentence |
denotes |
Open-label RCT (NCT04304053, recruiting). |
| T179 |
1253-1370 |
Sentence |
denotes |
Primary endpoint: incidence of secondary cases among contacts of a case and contacts of contacts (follow-up 14 days). |
| T180 |
1371-1470 |
Sentence |
denotes |
• Comparison of chloroquine plus favipiravir vs. favipiravir vs. placebo in patients with COVID-19. |
| T181 |
1471-1514 |
Sentence |
denotes |
Double-blind RCT (NCT04319900, recruiting). |
| T182 |
1515-1686 |
Sentence |
denotes |
Primary endpoints: (a) time to improvement/recovery and frequency of improvement/recovery (follow-up 10 days); (b) time to negative swab/sputum RT-PCR (follow-up 10 days). |
| T183 |
1687-1762 |
Sentence |
denotes |
• Comparison of favipiravir vs. standard of care in patients with COVID-19. |
| T184 |
1763-1812 |
Sentence |
denotes |
Open-label RCT (NCT04333589, not yet recruiting). |
| T185 |
1813-1925 |
Sentence |
denotes |
Primary endpoint: viral nucleic acid test negative conversion rate in nasopharyngeal swabs (follow-up 5 months). |
| T186 |
1926-2330 |
Sentence |
denotes |
• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. |
| T187 |
2331-2380 |
Sentence |
denotes |
Open-label RCT (NCT04303299, not yet recruiting). |
| T188 |
2381-2448 |
Sentence |
denotes |
Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks). |
